What Yapan Bio does

Yapan Bio Private Limited is a Contract Development and Manufacturing Organization (CDMO) founded in 2019 and headquartered at Genome Valley, Hyderabad, India. The company provides integrated services for vaccines and biologics/bio-therapeutics spanning early-stage process development, process characterization, and cGMP-compliant manufacturing for human clinical studies. Its technology stack supports multi-platform expression systems — mammalian cell culture, insect cell culture, and microbial fermentation — with bioreactor scale-up to 1000L, BSL-2+ containment for advanced vaccines and gene therapy products, and on-site aseptic fill-finish including lyophilization.

The company operates approximately 27,685 sq ft of infrastructure across three facilities: a 450 GMP Facility (~6,360 sq ft, 200L bioreactor scale, BSL-2+ suites), a Process Development Facility (~6,825 sq ft with three upstream suites and downstream/analytical labs), and a 270 GMP Facility (~13,500 sq ft with two manufacturing lines, up to 1000L bioreactor scale). Yapan Bio is a strategic asset within the Piramal Pharma ecosystem, with Piramal Pharma owning approximately 33.33% of the company following a December 2021 Rs 101.77 crore (~US$13.5M) investment for a 27.78% stake. The company serves a horizontal end-market of global biotechnology and biopharma companies requiring clinical-stage CDMO services, with revenue generated through project-based contracts using milestone-based or FTE/retainership engagement models. Yapan Bio's value proposition emphasizes integrated end-to-end services, BSL-2+ capabilities for differentiated modalities (gene therapy, advanced vaccines), and talent led by co-founders with >45 years of combined biopharma industry experience.

Name

Yapan Bio

Legal name

Yapan Bio Private Limited

Website

https://yapanbio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. CDMO Contract Services: Contract Development and Manufacturing Organization services providing process development, scale-up, process characterization and GMP manufacturing for vaccines and biologics/bio-therapeutics for human clinical studies. Revenue generated through project-based contracts with flexible partnership structures including milestone-based or FTE/retainership engagement models.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Yapan Bio is a Contract Development and Manufacturing Organization (CDMO) that provides integrated process development, scale-up, process characterization, and cGMP-compliant manufacturing services for vaccines and biologics/bio-therapeutics intended for human clinical studies. Services span from early-stage cell line and upstream/downstream development to GMP manufacturing using mammalian, insect, and microbial expression platforms, with on-site aseptic fill-finish and lyophilization capabilities.

Product overview

Yapan Bio is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from early-stage process development and scale-up to process characterization and GMP manufacturing for human clinical studies. The company's core offerings include Process Development, Process Characterization, and GMP Manufacturing services. These services support the development and manufacturing of Vaccines (recombinant vaccines, viral vector vaccines, RNA/DNA vaccines) and Biologics/Bio-therapeutics (gene therapy, monoclonal antibodies, therapeutic proteins). The company operates state-of-the-art facilities at Genome Valley, Hyderabad, India, including a 450 GMP Facility, Process Development Facility, and 270 GMP Facility with BSL-2+ containment capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Process Development Early-stage process development and scale-up services including cell line development, upstream and downstream manufacturing technologies, analytical method development, and stability studies for biotechnology and biopharma clients developing vaccines and biologics.
• Process Characterization Establishment and qualification of small-scale models for different unit operations, classification of process parameters and product quality attributes (Critical, Major, Minor), and Design of Experiments (DoE) to support regulatory filings for biotechnology and biopharma clients.
• GMP Manufacturing cGMP-compliant manufacturing services for vaccines and biologics including cell and virus seed banking, rocker, stirred tank and adherent cell bioreactors up to 1000L scale, single-use technologies, BSL-2+ containment suites, and aseptic fill/finish capabilities (lyophilization and liquid in vials) for clinical study supplies.
• Vaccines Development and Manufacturing CDMO service line focused on the development and manufacturing of recombinant vaccines (virus-like particles, nano-particles, protein antigens), viral vector based vaccines, and RNA/DNA vaccines for biotechnology and biopharma clients.
• Biologics/Bio-therapeutics Development and Manufacturing CDMO service line focused on the development and manufacturing of gene therapy products (oncolytic viruses, viral and non-viral vectors), monoclonal antibodies, therapeutic proteins, and other complex biologics for biotechnology and biopharma clients.

Quantifiable outcome

• GMP manufacturing for clinical studies supporting global biotechnology companies

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Piramal Pharma SolutionsmajorStrategic or Co-development PartnerYapan Bio operates as part of the Piramal Pharma network and is linked to Piramal Pharma Solutions. The company website shows integration with Piramal Pharma Solutions through shared branding and references. This partnership aligns with Piramal Pharma's growth strategy in the large molecule CDMO segment and provides Yapan Bio with access to a global CDMO network and customer base.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Piramal Pharma Solutions: Parent/strategic investor (33.33% owner) and adjacent CDMO with much broader small-molecule and biologics capabilities. Operates overlapping services but at vastly larger scale and global footprint, making it both a partner and a competitor for Yapan's clinical-stage clients.
• WuXi Biologics: Global biologics CDMO leader with end-to-end discovery, development, and manufacturing services at 2,000-20,000L bioreactor scale. Competes with Yapan for clinical-stage biologics work but operates at a vastly larger scale and broader geographic footprint.
• Samsung Biologics: South Korea-based global biologics CDMO offering process development and large-scale GMP manufacturing (up to 15,000L) for mAbs, vaccines, and complex biologics. Indirect competitor for Yapan's clients as programs advance from clinical to commercial scale.
• AGC Biologics: Global CDMO with mammalian and microbial-based biologics manufacturing for clinical and commercial supply. Competes for similar gene therapy and vaccine manufacturing contracts at higher scale and broader geographic reach.
• Lonza Group: Swiss-headquartered global CDMO leader across biologics, cell and gene therapy, and small molecules. Competes with Yapan for advanced therapy and vaccine manufacturing contracts, particularly as customer programs move toward late-stage and commercial supply.
• Catalent: Global CDMO with biologics and cell/gene therapy development and manufacturing capabilities across multiple sites. Overlaps with Yapan on gene therapy CDMO services and clinical-stage biologics fill-finish.

Direct peers

• Syngene International: India-based CRDO/CDMO providing biologics process development and manufacturing from mammalian cell culture, with global biotech clients. Direct competitor for India-sourced biologics CDMO work and similar size/scale tier, though Syngene has significantly broader capabilities and a public listing.
• Stelis Biopharma: India-based biologics CDMO offering process development and GMP manufacturing for vaccines, mAbs, and recombinant proteins from mammalian and microbial platforms. Closest direct head-to-head competitor in scale and service mix, also based in India.
• Vins Bioproducts: India-based vaccine and biologics manufacturer with CDMO services including process development and GMP manufacturing. Comparable Indian peer focused on vaccines and recombinant biologics, competing for similar client base in the region.

Regional players

• Celltrion: Korea-headquartered biosimilars and biologics manufacturer offering contract development and manufacturing for mAbs and recombinant proteins. Comparable in process technology focus though predominantly serves commercial biosimilar production.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/YapanBio
• LinkedInlinkedin.com/company/yapan-bio
• Instagraminstagram.com/yapan_bio_pvt_ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yapan Bio